The US administration has issued several executive orders (EOs) related to the nation’s pharmaceutical supply creating a trifecta of challenges for drug companies regarding pricing, onshoring, and tariffs. The most recent EO on May 12 seeks to lower the price of prescription drugs in the US by implementing a “most favored nation” (MFN) pricing requirement.
The order directs the Secretary of Health and Human Services to communicate price targets to pharmaceutical manufacturers within 30 days to bring US drug prices in line with comparably developed nations.
Separately, there is another EO directing the industry to increase US manufacturing and an in-process US Department of Commerce investigation, which is expected to result in tariffs on pharmaceuticals. The confluence of these factors has been called a “worst-case scenario” for the global pharmaceutical industry.
Why it matters: Price increases and supply chain disruptions are increasingly likely
myTCB® Members get exclusive access to webcasts, publications, data and analysis, plus discounts to events.
FOMC Decision: Do Three Dissents Mean a January Pause?
December 10, 2025
Fed December Decision: Not So Clear Cut
December 09, 2025
September Inflation Pause Bodes Well for Fed Cut
December 05, 2025
September Retail Sales Show Consumers Taking a Breather
November 25, 2025
New Truce Offers Stability after US–China Trade Plummeted in 2025
November 05, 2025
Fed Signals It May Need to Pause
October 29, 2025
Charts
The proliferation of easy-to-use generative AI requires that policymakers and business leaders each play an important role.
LEARN MORECharts
A hyperpolarized environment, diminished trust in our nation’s leaders.
LEARN MOREIN THE NEWS
Denise Dahlhoff on How CEOs Are Talking About Tariffs—without Saying “Tarif…
May 21, 2025
IN THE NEWS
Erin McLaughlin on Tariff Policy
April 07, 2025
IN THE NEWS
Erin McLaughlin on Reshoring Factors
April 05, 2025
IN THE NEWS
Erin McLaughlin on US Reshoring
April 02, 2025
IN THE NEWS
Erin McLaughlin: How policy uncertainty may exacerbate infrastructure chall…
March 19, 2025
IN THE NEWS
Erin McLaughlin discusses the latest on tariff policy
March 14, 2025